Premium
Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single‐institution study
Author(s) -
Schleiermacher Gudrun,
Delattre Olivier,
Peter Martine,
Mosseri Véronique,
Delonlay Pascale,
Vielh Philippe,
Thomas Gilles,
Zucker JeanMichel,
Magdelénat Henri,
Michon Jean
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960422)69:2<73::aid-ijc1>3.0.co;2-s
Subject(s) - loss of heterozygosity , neuroblastoma , relevance (law) , long arm , clinical significance , chromosome , genetics , medicine , biology , pathology , oncology , allele , gene , political science , cell culture , law
Neuroblastoma is characterized by a wide variability of its clinical course, and considerable effort has been made to identify factors determining outcome in this disease. In a series of 82 patients from a single institution, we have investigated the prognostic impact of multiple clinical, biological and genetic parameters. Univariate testing showed that advanced stage of disease, abdominal localization of the primary tumor, elevated urinary dopamine levels, N‐myc amplification (NMA) and loss of heterozygosity of chromosome 1p (LOH 1p) were related to a poor outcome. Most of these parameters were strong indicators of treatment failure in children younger than 12 months of age but none of them, apart from stage, had a significant prognostic impact in patients older than 12 months at diagnosis. Interestingly, the shorter survival time associated with the presence of 1p deletions or NMA appears to be more strongly linked to a poorer outcome after relapse or progression than to a shorter progression‐free interval. Although different types of LOH 1p have been described in neuroblastoma and may be associated with different biological features, as suggested by a different pattern of catecholamine secretion, tumors with LOH 1p present an aggressive clinical behavior, regardless of the type of LOH 1p. In this study, LOH 1p is an indicator of poor prognosis and identifies a larger population at risk than NMA alone. © 1996 Wiley‐Liss, Inc.